Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Find studies

Showing 601–625 of 654 studies in Health systems and care delivery (page 25 of 27) · 29,780 in the whole library · How the 0–100 score works

Download bibliography of the first 500 of these studies, in this order: BibTeX (.bib) · RIS (.ris)

Browse by subject, author or institution

Each number is how many studies that link shows, with your other filters kept.

What “Health systems and care delivery” covers

Health systems and care delivery — How health systems organise, coordinate and pay for dementia care, and where and how people with dementia actually receive it.

A note on reading research. One study is rarely the final word.

We try to note the size of a study, whether it was in humans or animals, and how early-stage the finding is. If a summary here doesn't make that clear, treat it with extra caution and check the original source.

The project exposes a discrepancy between the manner in which the nursing staff perceive use of restraints in an idealistic situation and in a realistic situation and the greater tendency to use restraints in the realistic situation than in the idealistic situation. 3 key findings →

Evidence: low

Amyloid immunotherapy with lecanemab and donanemab has been approved on the basis of statistically significant slowing of cognitive and functional decline in early Alzheimer's disease (1,2). 2 key findings →

Design: post-hoc analysis Evidence: low

ENRICH: a new innovation to facilitate dementia research in care homes

✓ Peer-reviewed alzhub usefulness score 25 out of 100. British Journal of Community Nursing 2012-06-01

There are currently almost three times as many care home beds as NHS hospital beds in England, and the number is projected to rise significantly by 2019 (Laing and Buisson, 2009). 1 key finding →

Evidence: low

Use of Restraints on Dementia Patients

✓ Peer-reviewed alzhub usefulness score 25 out of 100. JONA s Healthcare Law Ethics and Regulation 2003-12-01

The project exposes a discrepancy between the manner in which the nursing staff perceive use of restraints in an idealistic situation and in a realistic situation and the greater tendency to use restraints in the realistic situation than in the idealistic situation. 3 key findings →

Evidence: low

The Ukiyo Project is a collaborative initiative between the Faculty of Fine Arts at the Complutense University of Madrid (UCM) and the Faculty of Psychology at the University of Guanajuato (Mexico), aimed at promoting emotional well-being and mental health in the university environment through art. 2 key findings →

Evidence: low

A Life member is defined as a member who has given outstanding and distinguished service to the Association and to health promotion in Australia; where as a Fellow is a member who is regarded as having made a significant contribution to the purposes and objectives of the Association and to health promotion in Australia. 5 key findings →

Evidence: low

This study examined how the COVID-19 pandemic altered the sociologic, individual, and biologic personhood of residents living with dementia in nursing homes, guided by Buron’s (2008) Personhood Model for Dementia Care (PMDC). 5 key findings →

Evidence: low

Coding Options for Central Auditory Processing

✓ Peer-reviewed alzhub usefulness score 24 out of 100. ASHA Leader 2002-05-01

Scenario #1—Use of test battery code 92557 Comprehensive audiometry threshold $44.53 92567 Tympanometry $19.91 92568 Acoustic Reflex Testing $14.12 92569 Acoustic Reflex Decay Testing $15.20 92506 Evaluation of speech, language, voice, communication, and/or auditory processing $94.84 Total $188.60 CPT 92506, a code that represents a battery of tests, has a higher work value (i.e., higher reimbursement rate) associated with it than CPT codes for individual CAP tests (e.g., Staggered Spondaic Word test). 2 key findings →

Evidence: low

Delirium in the Nursing Home Setting

✓ Peer-reviewed alzhub usefulness score 24 out of 100. Psychiatry in Long-Term Care 2009-03-06

Although extensively studied in the acute care setting, the syndrome of delirium— also referred to as acute confusion—has been a subject of relatively few studies in the long-term care (LTC) setting. 1 key finding →

Evidence: low

Lawsuit Challenges Medicare Part D Transition Plan For Dual Eligibles

✓ Peer-reviewed alzhub usefulness score 22 out of 100. Psychiatric News 2005-12-16

But advocacy groups, including APA, have been bracing for enormous complications with transitioning these beneficiaries— some 2 million of whom are believed to have mental illness—into the new program. 1 key finding →

Evidence: low

↑ Change the filters

Where “Free full text” comes from

Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read

How the 0–100 score works — and why some entries are capped

This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.

  • Journal tier up to 10 pts
  • Journal's citation record up to 4 pts
  • Study design up to 12 pts
  • Strength of evidence up to 5 pts
  • Peer-review validation up to 10 pts
  • How recent up to 5 pts
  • Sample size up to 4 pts
  • Effect reported up to 3 pts
  • Studied in people up to 3 pts
  • Randomised / blinded up to 2 pts
  • Times cited up to 7 pts
  • Citations per year up to 5 pts
  • Impact for its field and year up to 6 pts
  • Cited by studies here up to 6 pts
  • Still being cited up to 4 pts
  • Senior author's track record up to 4 pts
  • Institution's track record up to 3 pts
  • Multi-centre collaboration up to 3 pts
  • Indexed in PubMed up to 2 pts
  • Free to read up to 2 pts

Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.

Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.

We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.

The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.

See the whole rubric drawn out → — four charts covering all 29,780 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.

What this library is — and isn't

This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 29,780 records, built mostly from automated pulls of Europe PMC (63.8% of the library) and OpenAlex (17.1%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.

1,037 records (3.5% of the library) are not peer-reviewed — 964 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.

See the full, machine-readable breakdown of this library's coverage →

Newest studies, as a dated timeline →    Atom feed